<DOC>
	<DOCNO>NCT00812981</DOCNO>
	<brief_summary>This observer-blind study design show immunological non-inferiority Thiomersal-free-processed pandemic influenza vaccine compare Thiomersal-containing-processed pandemic influenza vaccine .</brief_summary>
	<brief_title>A Study Evaluation GSK Biologicals ' Pandemic Influenza Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female age 18 60 year time first vaccination . Written inform consent obtain subject . Good general health establish medical history clinical examination enter study . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device Comprehension study requirement , ability comprehend comply procedure collection short longterm safety data , express availability require study period , ability willingness attend schedule visit . If subject female , must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Evidence substance abuse neurological psychiatric diagnosis , even clinically stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Diagnosed cancer , treatment cancer , within 3 year . An oral temperature ≥ 37.8 º C acute symptom great `` mild '' severity schedule date first vaccination . Any confirm suspected immunosuppressive immunodeficient condition include history human immunodeficiency virus ( HIV ) infection . Receipt systemic glucocorticoid ( prednisone ≥ 5 mg/kg/day 14 consecutive day ) within 1 month study enrolment , cytotoxic immunosuppressive drug within 6 month study enrolment . Any significant disorder coagulation treatment Coumarin derivatives Heparin . Administration vaccine within 30 day study enrolment . Previous administration H5N1 vaccine . Previous administration vaccine adjuvant similar use investigational vaccine . Use investigational nonregistered product ( drug vaccine ) plan participation another investigational study within 30 day prior study enrolment , 180 day follow first test article dose . Use investigational nonregistered product immunosuppressive property exclusionary time trial . Receipt immunoglobulins and/or blood product within 3 month study enrolment plan administration product study period . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Known pregnancy positive urine betahuman chorionic gonadotropin ( βhCG ) test result prior either vaccination . Lactating woman . Women child bear potential lack history reliable contraceptive practice . The provision history NOT replace requirement perform , obtain negative result pregnancy urine test prior treatment . Known use analgesic antipyretic medication within 12 hour prior first treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pandemic influenza</keyword>
</DOC>